tradingkey.logo
tradingkey.logo
Search

Becton Dickinson and Co

BDX
Add to Watchlist
149.400USD
-3.860-2.52%
Close 05/08, 16:00ETQuotes delayed by 15 min
42.64BMarket Cap
37.68P/E TTM

Becton Dickinson and Co

149.400
-3.860-2.52%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.52%

5 Days

+0.24%

1 Month

-3.59%

6 Months

+6.90%

Year to Date

-2.04%

1 Year

+13.74%

Key Insights

Becton Dickinson and Co's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 29 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 189.24.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Becton Dickinson and Co's Score

Industry at a Glance

Industry Ranking
29 / 206
Overall Ranking
97 / 4498
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Becton Dickinson and Co Highlights

StrengthsRisks
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 21.84B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 71.28%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 71.28%.
Fairly Valued
The company’s latest PE is 38.65, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 240.71M shares, decreasing 16.42% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.15K shares of this stock.

Analyst Rating

Based on 18 analysts
Buy
Current Rating
189.237
Target Price
+30.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Becton Dickinson and Co News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Becton Dickinson and Co Info

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Ticker SymbolBDX
CompanyBecton Dickinson and Co
CEOPolen (Thomas E)
Websitehttps://www.bd.com/
KeyAI